For adult patients with relapsed or refractory CLL or SLL after at least 2 prior therapies
POWER & PRECISION
The FIRST AND ONLY oral dual PI3K-δ and PI3K-γ inhibitor
SEE CLINICAL TRIAL DATA
COPIKTRA demonstrated >7-month median PFS advantage vs ofatumumab in the pivotal phase 3 DUO trial
VIEW SAFETY PROFILE
Information about the Boxed Warning, additional Warnings and Precautions, and other adverse reactions
ACCESS PATIENT CASES
Heavily pretreated and high-risk patients responded to single-agent duvelisib
CLL, chronic lymphocytic leukemia; δ, delta; γ, gamma; PI3K, phosphoinositide 3-kinase;
SLL, small lymphocytic lymphoma.